The FDA on May 13th approved the dual GIP-GLP1-agonist Mounjaro® (tirzepatide) from Eli Lilly for diabetes following the completion of the SURPASS studies (e.g. SURPASS-2 NCT03987919). Mounjaro® is administered as a weekly injection just like the GLP1-agonist Ozempic® (semaglutide) from Novo Nordisk for diabetes. The table below summarizes products from Eli Lilly and Novo Nordisk …
Tag Archives: healthcare
Novo Nordisk 2021Q3 – Wegovy® bottlenecks
Novo Nordisk continues to succeed in the GLP-1 space with semaglutide (Ozempic®, Rybelsus® and Wegovy®). Highlights of the quarter include initiation of phase 3a trials with oral semaglutide in obesity and ziltivekimab in cardiovascular disease. Novo Nordisk now has late stage clinical trials in all of their therapy areas. Ozempic® continues to be one of …
Continue reading “Novo Nordisk 2021Q3 – Wegovy® bottlenecks”
Novo Nordisk Q2 saw approval of Wegovy® and continued growth of Ozempic® sales
Novo Nordisk sales and operating profit grew at 12% and 9%, respectively, at constant exchange rates. The FDA approved the once-weekly injectable anti-obesity drug Wegovy® (semaglutide) on June 4th. The figures below summarize the global sales for Novo Nordisk by geography, by drug and by drug class. All geographic markets have experienced growth, but Victoza® …
Continue reading “Novo Nordisk Q2 saw approval of Wegovy® and continued growth of Ozempic® sales”
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19
Novo Nordisk has gained market share in diabetes (29.2%), GLP-1 (49.9%) and insulin (44.5%). The gain in market share has happened with a change in market value in the US as a backdrop; i.e. GLP-1 up and insulin down. As a consequence approximately 70% of sales in the US did not exist 5 years ago. …
Keytruda®, Ozempic® and the other blockbuster drugs of the 3rd quarter of 2019
The pharmaceutical companies AbbVie and Novo Nordisk presented their quarterly results today and concluded the earnings season for the major pharmaceutical companies. There are currently more than 50 blockbuster drugs in the world with annual sales exceeding a billion US dollars. Here the best selling and fastest growing medications of the third quarter of 2019 …
Continue reading “Keytruda®, Ozempic® and the other blockbuster drugs of the 3rd quarter of 2019”
Diabetes and the third quarter of 2019
Novo Nordisk and Eli Lilly have both reported their Q3 results. Below are some of the headlines related to their diabetes business. Novo Nordisk OG2023SC, an oral GLP-1 analogue, has been discontinued based on encouraging results for an enhanced oral semaglutide formulation. US FDA decision on cardiovascular indication for Rybelsus® is expected in the first …
Roche reports very strong sales growth in the first nine months of 2019 – outlook raised
Roche issued a press release on its nine month sales with the following headlines. Group sales increase 10% at constant exchange rates and 9% in Swiss francs, due to new products Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta Diagnostics Division sales grow 4%, primarily …
J&J tops estimates
Johnson & Johnson [$JNJ] issued a press release before the market opened on its third quarter results with the following headlines: Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* EPS of $1.81 increased 25.7%; adjusted EPS of $2.12 increased 3.4%* Company increasing Full Year Sales …
UnitedHealth beats estimates and raises outlook
United Healthcare [$UNH] issued a press release on its quarterly results before the market opened with the following headlines: Total Revenues of $60.4 Billion Grew by 7% or $3.8 Billion Year-over-Year Operating Earnings Grew 9% to $5.0 Billion, Including Double-Digit Growth Rates in Each Optum Business Net Earnings Per Share were $3.67, Adjusted Net Earnings …
Continue reading “UnitedHealth beats estimates and raises outlook”